SSTR2-targeted radionuclide therapy, commonly referred to as ‘peptide receptor radionuclide therapy’ (PRRT) has been acknowledged by the European Association of Neuro-oncology (EANO) as a salvage therapy for treatment-refractory meningioma [3], as outlined in recent practice guidelines [8]. This evidence concerns the gene SSTR2 and meningioma.